6.3.2024 16:33:34 CET | Demant A/S |
Forløb af generalforsamling
Selskabsmeddelelse nr. 2024-06
6. marts 2024
Beslutninger på den ordinære generalforsamling
Demant A/S har i dag afholdt ordinær generalforsamling, der blev afholdt fysisk på selskabets adresse, Kongebakken 9, 2765 Smørum.
I sin tale på generalforsamlingen redegjorde bestyrelsens formand, Niels B. Christiansen, for koncernens udvikling i 2023. Beretningen er tilgængelig på www.demant.com. I sin tale sagde formanden blandt andet:
“Vi kan se tilbage på et år, hvor vi leverede det historisk bedste resultat for koncernen nogensinde. Og det er samtidig med, at vi endnu en gang har hjulpet mange mennesker ved at behandle deres høretab. Vi er glade for, at vi allerede igen her i februar har kunnet annoncere endnu et nyt banebrydende flagskibsprodukt, Oticon Intent, som vil understøtte væksten i 2024.
Det understreger værdien af vores produkter og services og ikke mindst det positive bidrag, vi giver til samfundet. Det er også et vidnesbyrd om, at vores engagerede medarbejdere hver dag arbejder for at realisere vores ambition om at forbedre så mange liv som muligt. Vores ambition og omsorg for menneskers høresundhed og velbefindende går hånd i hånd med også at passe på vores samfund og planeten.”
Alle bestyrelsens forslag blev vedtaget af generalforsamlingen. Dette medførte blandt andet følgende beslutninger:
At selskabets årsrapport for 2023 blev godkendt, og at hele årets overskud, DKK 1.375 mio., overføres til selskabets reserver.
At vederlagsrapporten for 2023 blev godkendt.
At bestyrelseshonoraret forbliver det samme som i 2023.
At Niels B. Christiansen, Niels Jacobsen, Sisse Fjelsted Rasmussen og Kristian Villumsen blev genvalgt som bestyrelsesmedlemmer.
At selskabets revisionsfirma PricewaterhouseCoopers Statsautoriseret Revisionspartnerselskab (PwC), blev genvalgt, og at PwCs opgaver fremadrettet tillige vil omfatte afgivelse af erklæring om bæredygtighedsrapportering i ledelsesberetningen.
At aldersgrænsen i vedtægterne udgår.
At selskabets aktiekapital nedsættes med nominelt DKK 569.929,60 svarende til selskabets beholdning af egne aktier pr. 5. februar 2024, fraregnet aktier til dækning af ledelsens fastholdelsesprogram. Beholdningen af egne aktier er erhvervet som led i selskabets aktietilbagekøb i 2023. Som konsekvens af kapitalnedsættelsen ændres vedtægternes pkt. 4.1 senest fire uger efter udløbet af fristen for kreditorers anmeldelse af krav, således at det herefter af pkt. 4.1 vil fremgå, at selskabets aktiekapital udgør DKK 44.217.958,40.
At bestyrelsen blev bemyndiget til indtil næste ordinære generalforsamling at lade selskabet tilbagekøbe aktier med en pålydende værdi af indtil 10 % af aktiekapitalen.
Efter generalforsamlingen konstituerede bestyrelsen sig med Niels B. Christiansen som formand og Niels Jacobsen som næstformand. Sisse Fjelsted Rasmussen fortsætter som formand for revisionsudvalget.
I henhold til paragraf 3.8.1 i Nasdaqs Nordic Main Market Rulebook for Issuers of Shares skal Demant hermed give følgende oplysninger som opfølgning på det aktiebaserede program for direktionen, der er en del af direktionens vederlag:
Beskrivelse af programmet
Et langsigtet incitamentsprogram i form af Restricted Stock Units (RSU’er), som efter optjening konverteres 1:1 til aktier i selskabet. Der henvises til selskabets vederlagspolitik for en detaljeret beskrivelse af programmet.
Optjeningsperiode
2024-2027, dvs. tre år
Performance-periode
2024, dvs. et år
Aktiekurs
DKK 351,21, dvs. gennemsnittet af kurserne noteret på Nasdaq i København de første fem handelsdage efter offentliggørelse af Demants årsrapport for 2023.
Samlet antal tildelte RSU’er
50.289
Programmets teoretiske markedsværdi
DKK 17.662.000 baseret på den aktiekurs, der anvendes til beregning af tildelingen. Beløbet repræsenterer den maksimale udbetaling, som justeres i forhold til performance-kriterierne.
Yderligere information:
Søren Nielsen, koncernchef og adm. direktør
Telefon +45 3917 7300
www.demant.com
Øvrige kontaktpersoner:
René Schneider, CFO
Peter Pudselykke, Head of Investor Relations
Henrik Axel Lynge Buchter, Manager of External Communications
Kontakter
Henrik Axel Lynge Buchter, External Communication Manager, Corporate Communication & Sustainability, +45 2264 9982, heey@demant.com
Om Demant A/S
Demant is a world-leading hearing healthcare group that offers solutions and services to help people with hearing loss connect with the world around them. In every aspect, from hearing devices, hearing implants, diagnostics to audio and video solutions and hearing care all over the world, Demant is active and engaged. Our innovative technologies and know-how help improve people’s health and hear-ing. We create life-changing differences through hearing health.
Vedhæftninger
2024-06 Beslutninger på den ordinære generalforsamling.pdf
6.3.2024 16:33:34 CET | Demant A/S |
Decisions of general meeting
Company announcement no 2024-06
6 March 2024
Decisions of Annual General Meeting
Today, Demant A/S held its annual general meeting, which took place at the company’s premises, Kongebakken 9, 2765 Smørum, Denmark.
In his address, the Chair of the Board of Directors, Niels B. Christiansen, gave an account of the Group’s development in 2023. The report is available on www.demant.com. He said among other things:
“We can look back on a year where we achieved the best results in the history of the company, while also helping an incredible number of people by treating their hearing loss. We are extremely happy that already in February, we were able to announce another new and groundbreaking flagship product, Oticon Intent, which will support growth in 2024.
This underscores the value of our products and services and not least the positive contribution we make to society. It is also a testament to how our engaged employees work every day to realise our ambition to improve as many lives as possible. Our ambition and care for people’s hearing health and well-being go hand in hand with caring for society and the planet.”
All proposals put forward by the Board of Directors were adopted by the general meeting, implying among others the following decisions:
The company’s Annual Report 2023 was approved, and the year’s profit, DKK 1,375 million, will be transferred to the company’s reserves.
The Remuneration Report for 2023 was approved.
The proposal for the Director’s fee to remain the same as in 2023 was adopted.
Niels B. Christiansen, Niels Jacobsen, Sisse Fjelsted Rasmussen and Kristian Villumsen were re-elected to the Board of Directors.
The company’s auditors, PricewaterhouseCoopers Statsautoriseret Revisionspartnerselskab (PwC), was re-elected. A proposal to the effect that in the future, PwC’s tasks will also include providing an opinion on the assurance of sustainability reporting in the management’s review was adopted.
The age limit in the Articles of Association will be removed.
The company’s share capital will be reduced by nominally DKK 569,929.60, corresponding to the company’s holding of treasury shares as of 5 February 2024, less shares to cover management’s retention programme. The company’s holding of treasury shares was acquired during 2023 as part of the company’s share buy-back scheme. As a result of the capital reduction, article 4.1 of the Articles of Association will be amended no later than four weeks after expiry of the deadline for the filing of claims by creditors, which means that upon expiry of this deadline, it will appear from article 4.1 that the company’s share capital is DKK 44,217,958.40.
Until the next ordinary general meeting, the Board was authorised to let the company buy back shares with a nominal value of up to 10% of the share capital.
After the general meeting, the Board of Directors elected Niels B. Christiansen Chair and Niels Jacobsen Vice Chair of the Board. Sisse Fjelsted Rasmussen continues as chair of the audit committee.
Pursuant to rule 3.8.1 in Nasdaq’s Nordic Main Market Rulebook for Issuers of Shares, Demant hereby provides the following information as follow-up on the Executive Board’s share-based programme, which is part of the Executive Board’s remuneration:
Description of the programme
A long-term incentive programme in the form of restricted stock units (RSUs), which will be converted into shares in the company on a 1:1 ratio at vesting. Please refer to the Remuneration Policy for a detailed description of the programme.
Vesting period
2024-2027, i.e. three years
Performance period
2024, i.e. one year (the first year of the vesting period)
Share price used for grant calculation
DKK 351.21, i.e. the average share price quoted on Nasdaq Copenhagen of the first five trading days following the publication of Demant’s Annual Report 2023.
Total number of RSUs granted
50,289
Theoretical market value of the programme
DKK 17,662,000 based on the share price used for grant calculation and representing the maximum payout to be adjusted based on performance criteria.
Further information:
Søren Nielsen, President & CEO
Phone +45 3917 7300
www.demant.com
Other contacts:
René Schneider, CFO
Peter Pudselykke, Head of Investor Relations
Henrik Axel Lynge Buchter, External Communication Manager
Contacts
Henrik Axel Lynge Buchter, External Communication Manager, Corporate Communication & Sustainability, +45 2264 9982, heey@demant.com
About Demant A/S
Demant is a world-leading hearing healthcare group that offers solutions and services to help people with hearing loss connect with the world around them. In every aspect, from hearing devices, hearing implants, diagnostics to audio and video solutions and hearing care all over the world, Demant is active and engaged. Our innovative technologies and know-how help improve people’s health and hear-ing. We create life-changing differences through hearing health.
Attachments
2024-06 Decisions of annual general meeting.pdf
